Previous 10 | Next 10 |
Abiomed (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, announces the 1,000th patient has been treated with the Impella heart pump in Japan. The Impella 2.5 and Impella 5.0 heart pumps are approved for the treatment of drug-resistant acute heart failure and ...
New York, New York--(Newsfile Corp. - October 2, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in ABIOMED, Inc. (NASDAQ: ABMD) ("ABIOMED" or the "Company") of the October 7, 2019 deadline to seek the role of lead plaintiff in a federal securities ...
Medical device companies often fly under the radar of individual investors. That's a shame, as medical device companies have unique attributes that can make them wonderful long-term holdings. Consider ShockWave Medical (NASDAQ: SWAV) , a newly public company focused on cardiovascular dis...
The following slide deck was published by Abiomed, Inc. in conjunction with this Read more ...
Data presented today from the National Cardiogenic Shock Initiative Study (NCSI) on 250 consecutive AMI cardiogenic shock (AMICS) patients from 49 sites demonstrates 72% survival at discharge with 98% native heart recovery. The patients were treated with the NCSI protocol, which includes pl...
Abiomed (NASDAQ: ABMD) announces the results of PROTECT III, the ongoing, prospective, single-arm FDA post-approval study for the PMA approval of Impella 2.5 and Impella CP in high-risk PCI. PROTECT III follows the PROTECT II Randomized Controlled Trial (RCT). This press release features ...
Abiomed’s (NASDAQ: ABMD) newest heart pump, the Impella 5.5 with SmartAssist, has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for safety and efficacy in the therapy of cardiogenic shock for up to 14 days. This press release features multimedia. View t...
New York, New York--(Newsfile Corp. - September 23, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Abiomed, Inc. (NASDAQ: ABMD) ("Abiomed" or the "Company") of the October 7, 2019 deadline to seek the role of lead plaintiff in a federal securitie...
The highest court in Germany, the Federal Court of Justice, recently ruled in favor of Abiomed (NASDAQ: ABMD) in a patent challenge filed by Thoratec in 2015 and validated the strengths of Abiomed’s Impella-related patents. These patents are also the subject of a separate patent in...
Abiomed (NASDAQ:ABMD) will highlight the benefits of complete revascularization with Protected PCI and the value of Impella protocol-based treatment for survival and native heart recovery in cardiogenic shock patients at the 31 st Transcatheter Cardiovascular Therapeutics (TCT) conference ...
News, Short Squeeze, Breakout and More Instantly...
Abiomed (Nasdaq: ABMD) announces the United States Food and Drug Administration (FDA) has approved the version of Impella ECP that will be used in the Impella ECP Pivotal Trial, and the first two patients have been enrolled in the trial. Amir Kaki, MD, director of mechanical circulatory support...
Steel Dynamics Set to Join S&P 500; Super Micro Computer to Join S&P MidCap 400 Steel Dynamics Set to Join S&P 500; Super Micro Computer to Join S&P MidCap 400 PR Newswire NEW YORK , Dec. 19, 2022 /PRNewswire/ -- S&P MidCap 400 constituent...
Abiomed (Nasdaq: ABMD) announces the first three patients in the world have been treated with Impella RP Flex with SmartAssist, Abiomed’s newest heart pump for patients experiencing right heart failure. All three patients have now been successfully weaned off Impella support and two have...